The Food and Drug Administration’s final guidance, “Circumstances that Constitute Delaying, Limiting, or Refusing a Drug Inspection,” describes manufacturer actions the agency views as “delaying, denying, or limiting inspection, or refusing to permit entry or inspection.”
The final document supersedes the draft document the agency issued in 2022 which expanded the FDA’s policy on inspections of...